Implants teach the immune system to ID cancer

Researchers at Harvard University are experimenting with a way to stimulate the immune system to recognize and fight cancers, and they may have found a way to do it using doped implants.

These implants are tiny biodegradable discs full of something known as granulocyte-macrophage colony-stimulating factor, a substance that attracts the immune system's dendritic cells—the same cells that lock on to bacteria and viruses, then carry them to the lymph nodes—where T-cells are waiting to kill them.

Unfortunately, dendritic cells can spot all manner of foreign microbes, but they can't identify cancer.

The Harvard team is trying to change that by "teaching" the cells to identify cancer by removing molecules of the cancerous tumor via biopsy, then attaching them to the biodegradable discs, along with a substance the body associates with infection, cytosine-guanosine oligonucleotide.

The dendritic cells are attracted by the granulocyte-macrophage colony-stimulating factor, only to find themselves caught in the "spongy implant's pores", where they are exposed to the cancerous molecules and the cytosine-guanosine oligonucleotide. Cued by the latter chemical, they then take the cancer cells to the killer T-cells in the lymph nodes to have them killed.

The Harvard team published a highly successful study with mice in the journal Nature Materials earlier in 2009 and will begin human clinical trials next summer.

Source: The Economist

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap